Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study

• Main Authors: Garbe,Edeltraut, Hoti,Fabian, Schink,Tania, Svendsen,Kristian, Al-Eid,Haydar, Arkhammar,Per, Carlholm,Marie, Fjällbrant,Harald, Franzén,Stefan, Hedlund,Cecilia, Kollhorst,Bianca, Kumar,Atul, Lobier,Muriel, Mushnikov,Vasili, Persson,Tore, Qiao,Xu, Salosensaari,Aaro, Schäfer,Wiebke, Sicignano,Nicholas, Johansson,Gunnar, Dareng,Eileen
• Format: Article in Journal/Newspaper
• Language: English
• Published: Dove Press 2024
• Subjects: International Journal of Chronic Obstructive Pulmonary Disease; Arctic; Gunnar; Norway; Persson; Arctic University of Norway; UiT The Arctic University of Norway
• Online Access: https://www.dovepress.com/long-term-safety-of-roflumilast-in-patients-with-chronic-obstructive-p-peer-reviewed-fulltext-article-COPD

Edeltraut Garbe,1 Fabian Hoti,2 Tania Schink,1 Kristian Svendsen,3 Haydar Al-Eid,4 Per Arkhammar,5 Marie Carlholm,6 Harald Fjällbrant,6 Stefan Franzén,7,8 Cecilia Hedlund,9 Bianca Kollhorst,10 Atul Kumar,11 Muriel Lobier,2 Vasili Mushnikov,2 Tore Persson,9 Xu Qiao,2 Aaro Salosensaari,12 Wiebke Schäfer,1 Nicholas M Sicignano,13 Gunnar Johansson,14 Eileen O Dareng15 1Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 2Biostatistics, Scientific Services, Real World Solutions, IQVIA, Espoo, Finland; 3Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway; 4United States Navy, Naval Medical Center, Portsmouth, Virginia, USA; 5Global Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden; 6Late-Stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 7BPM Evidence Statistics, Medical Evidence, BioPharmaceuticals Medical, Gothenburg, Sweden; 8School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 9Biometrics, Late-stage Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden; 10Department Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; 11Global Patient Safety Biopharma, AstraZeneca, Bangalore, India; 12Biostatistics, Scientific Services, Real World Solutions, IQVIA, Turku, Finland; 13Health ResearchTx LLC, Trevose, Pennsylvania, USA; 14Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; 15Safety Epidemiology and Risk Management, AstraZeneca, Cambridge, UKCorrespondence: Eileen O Dareng, AstraZeneca, City House, 126-130 Hills Road, Cambridge, CB2 1RY, United Kingdom, Tel [phone], Email [e-mail]: This study evaluated the long-term safety of roflumilast in patients with chronic obstructive pulmonary disease ...